| Characteristics |
N =127 |
| Female , N (%) |
63 (50) |
| Median age; years (IQR) |
41 (37-47) |
| Subject older than 50 years old, N (%) |
23 (18) |
| Median BMI (kg/m), IQR |
21.9 (19.6-24.6) |
| Median weight (BW) (kg), IQR |
60(50-67) |
| Subject with BW> 60 kg, N (%) |
55 (48) |
Regimen prior to switching to ATV/r 200/100, N (%)
ATV/r 300/100 mg
ATV 400 mg
IDV/r
LPV/r
SQV/r
EFV or NVP failure |
61(48)
8 (6)
7 (6)
37 (29)
9 (7)
5 (4) |
| Reasons for switching to ATV/r 200/100
ATV plasma concentration >0.85 mg/L
Asymptomatic hyperbilirubinemia
Clinical Jaundice (symptomatic patients)
Other (pill burden from other boosted PIs, low BW, or reduced cost) |
44 (35)
20 (16)
10 (8)
53 (42) |
| Concomitant TDF
TDF 300 mg alterative day
TDF 300mg once daily |
118 (93)
34 (29)
84 (71) |
| Median baseline CD4, cells/µL (IQR) |
486 (368-696) ( range 14-1854) |
| Baseline HIV-RNA <50 copies/ml, N (%) |
116 (91.3) |
| Median bilirubin, mg/dl (IQR) |
1.3 (0.8-2.6) |
| Median eGFR, ml/min/1.73m2(IQR) |
83 (74-99) |
